Axcella Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
11
- Latest Deal Type
-
Liquidation
Axcella General Information
Description
Operator of a clinical-stage biotechnology company designed to help identify protein nutrients within the human diet that have potent pharmacological effects. The company focuses on treating complex diseases and improving health using endogenous metabolic modulators, or EMM, compositions.
Contact Information
Website
www.axcellahealth.comCorporate Office
- 840 Memorial Drive
- Entrance on Blackstone Street, Third Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 840 Memorial Drive
- Entrance on Blackstone Street, Third Floor
- Cambridge, MA 02139
- United States
Axcella Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Bankruptcy: Liquidation | 28-Dec-2023 | Completed | Bankruptcy: Liquidation | |||
| 10. 2PO | 16-Mar-2022 | Completed | Generating Revenue | |||
| 9. 2PO | 14-May-2020 | Completed | Generating Revenue | |||
| 8. IPO | 09-May-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series E) | 30-Nov-2018 | Completed | Generating Revenue | |||
| 6. Debt Refinancing | 09-Jan-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 24-Feb-2016 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series C) | 17-Feb-2015 | Completed | Clinical Trials - General | |||
| 3. Debt - General | 30-Jun-2014 | $7M | $30M | Completed | Clinical Trials - General | |
| 2. Early Stage VC (Series B) | 13-Feb-2014 | $12.2M | $23M | Completed | Clinical Trials - General |
Axcella Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | 4,737,041 | $0.001000 | $0.21 | $2.59 | $2.59 | 1x | $2.59 | 10.18% |
| Series A | 5,874,334 | $0.001000 | $0.16 | $1.95 | $1.95 | 1x | $1.95 | 12.62% |
Axcella Comparisons
Industry
Financing
Details
Axcella Competitors (101)
One of Axcella’s 101 competitors is Genevant, a Corporate Backed or Acquired company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genevant | Corporate Backed or Acquired | Vancouver, Canada | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| 4D pharma | Corporation | Leeds, United Kingdom |
Axcella Patents
Axcella Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024030909-A1 | Biomarkers of amino acid composition treatment response in long covid | Inactive | 01-Aug-2022 | ||
| WO-2024026307-A1 | Biomarker for long covid and fatigue | Inactive | 25-Jul-2022 | ||
| WO-2023009444-A1 | Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19 | Inactive | 26-Jul-2021 | ||
| WO-2022266480-A1 | Methods of predicting liver fat content and uses thereof | Inactive | 17-Jun-2021 | ||
| US-20230089723-A1 | Amino acid compositions and methods for muscle and myotube modulation | Inactive | 06-Mar-2020 | A61P21/00 |
Axcella Signals
Axcella ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Axcella FAQs
-
When was Axcella founded?
Axcella was founded in 2008.
-
Where is Axcella headquartered?
Axcella is headquartered in Cambridge, MA.
-
What is the size of Axcella?
Axcella has 11 total employees.
-
What industry is Axcella in?
Axcella’s primary industry is Biotechnology.
-
Is Axcella a private or public company?
Axcella is a Private company.
-
What is Axcella’s current revenue?
The current revenue for Axcella is .
-
How much funding has Axcella raised over time?
Axcella has raised $325M.
-
Who are Axcella’s competitors?
Genevant, Vedanta Biosciences, Cellaion, Enterome, and 4D pharma are some of the 101 competitors of Axcella.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process